Daily News

Most Recent

Discrimination in academia

By | July 31, 2007

See what other readers had to say about the decision of a faculty member and administrator to resign over conditions at MIT


Doubts over UK research head

By | July 31, 2007

Parliamentary committee questions MRC chair's leadership


Gene therapy trial on hold

By | July 31, 2007

Researchers say viral vector unlikely to be culprit in patient's death

1 Comment

Regulators evolve faster than genes

By | July 31, 2007

Mutations in regulatory sequences may be the main drivers of species divergence


Yale dumps BioMed Central

By | July 31, 2007

The research institution decides not to renew membership to the open access publishing company


Special feature: How should scientists sell science?

By | July 30, 2007

Tell us whether you think researchers should change the way they communicate hot-button issues to the public


Who will replace Don Kennedy?

By | July 30, 2007

Leading scientists speculate as search for new Science editor-in-chief begins


Designing buildings, using biology

By | July 27, 2007

Today's architects turn to biology more than ever. Here's why


Authors retract Science paper

By | July 26, 2007

Lead author found guilty of misconduct in embryonic cell lineage paper called into question over a year ago


Last chance to vote for the Best Places to Work in Academia

By | July 26, 2007

Add your voice to the poll and help us place your institution in the ranking. Survey closes Sept. 4

1 Comment

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham